Among various anti-BCMA therapeutic strategies, this review will specifically address the current developmental status of anti-BCMA immunotoxin as a potential therapeutic option for the treatment of relapsed and refractory multiple myeloma. Here, TNFRSF17 is linked to plasma cell myeloma.